Brain Tumors

Supratentorial Craniotomy

Survival: Supratentorial Craniotomy

2016 – 2020

The 30- and 180-day survival rates were 100% and 99%, respectively, for 2020.

Supratentorial Craniotomy: Inpatient Mortality

2016 – 2020

ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.

Inpatient mortality remained lower than expected, continuing the trend during the past 5 years. N = number of supratentorial craniotomies performed for brain tumor per year. For 2020 the inpatient mortality was 0.47% while the expected mortality was 11%.

Supratentorial Craniotomy: Length of Stay

2016 – 2020

LOS = length of stay

ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.

Average length of stay remained below target, continuing the trend during the past 5 years.

Karnofsky Performance Scale (N = 50)

2020

Functional status is measured by the Karnofsky Performance Scale (KPS), a widely used 11-point scale correlating to percentage values from 100% (no evidence of disease, no symptoms) to 0% (death). Performance status was stable or improved in approximately 84% of patients immediately after supratentorial craniotomy. Change in KPS status was defined as a change of ≥ 20 points.

Supratentorial Craniotomy for Glioma

2016 – 2020

The 30- and 180-day survival rates for supratentorial craniotomy for glioma were 100% and 98%, respectively, for 2020.

Supratentorial Craniotomy for Meningioma

2016 – 2020

Both the 30- and 180-day survival rates for supratentorial craniotomy for meningioma were 100% for 2020.

Supratentorial Craniotomy for Metastasis

2016 – 2020

The 30- and 180-day survival rates for supratentorial craniotomy for metastases were 100% and 98%, respectively, for 2020.